Literature DB >> 17080031

Drug discovery in dementia: the role of rodent models.

Debby Van Dam1, Peter Paul De Deyn.   

Abstract

Recent advances in the understanding of the pathophysiological mechanisms underlying Alzheimer's disease have pointed to novel strategies for drug development. Animal models have contributed considerably to these advances, and will have a key role in the evaluation of therapeutics that could have the potential not just to alleviate the dementia associated with Alzheimer's disease, but to modify the disease process. Here, we summarize and critically evaluate current rodent models of dementia, and discuss their role in drug discovery and development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17080031     DOI: 10.1038/nrd2075

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  52 in total

1.  3,6'-Dithiothalidomide, a new TNF-α synthesis inhibitor, attenuates the effect of Aβ1-42 intracerebroventricular injection on hippocampal neurogenesis and memory deficit.

Authors:  Isabella Russo; Luca Caracciolo; David Tweedie; Sang-Ho Choi; Nigel H Greig; Sergio Barlati; Francesca Bosetti
Journal:  J Neurochem       Date:  2012-07-25       Impact factor: 5.372

Review 2.  Alzheimer's disease: pathophysiology and applications of magnetic nanoparticles as MRI theranostic agents.

Authors:  Houshang Amiri; Kolsoum Saeidi; Parvin Borhani; Arash Manafirad; Mahdi Ghavami; Valerio Zerbi
Journal:  ACS Chem Neurosci       Date:  2013-09-26       Impact factor: 4.418

3.  Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.

Authors:  Luis Escribano; Ana-María Simón; Esther Gimeno; Mar Cuadrado-Tejedor; Rakel López de Maturana; Ana García-Osta; Ana Ricobaraza; Alberto Pérez-Mediavilla; Joaquín Del Río; Diana Frechilla
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

Review 4.  Pharmacogenomics and therapeutic prospects in dementia.

Authors:  Ramón Cacabelos
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-03       Impact factor: 5.270

Review 5.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Maturation and phenotype of pathophysiological neuronal excitability of human cells in tau-related dementia.

Authors:  Olga Kopach; Noemí Esteras; Selina Wray; Dmitri A Rusakov; Andrey Y Abramov
Journal:  J Cell Sci       Date:  2020-05-27       Impact factor: 5.285

Review 7.  Neurotrophic factors in neurodegenerative disorders : potential for therapy.

Authors:  Fabio Fumagalli; Raffaella Molteni; Francesca Calabrese; Paola Francesca Maj; Giorgio Racagni; Marco Andrea Riva
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 8.  Unfolded Protein Response and PERK Kinase as a New Therapeutic Target in the Pathogenesis of Alzheimer's Disease.

Authors:  Wioletta Rozpedek; Lukasz Markiewicz; J Alan Diehl; Dariusz Pytel; Ireneusz Majsterek
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

Review 9.  Convergence of amyloid-beta and tau pathologies on mitochondria in vivo.

Authors:  Anne Eckert; Kathrin L Schulz; Virginie Rhein; Jürgen Götz
Journal:  Mol Neurobiol       Date:  2010-03-09       Impact factor: 5.590

10.  Animal models for Alzheimer's disease and frontotemporal dementia: a perspective.

Authors:  Jürgen Götz; Naeman N Götz
Journal:  ASN Neuro       Date:  2009-11-09       Impact factor: 4.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.